Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1896974 | 0.97 | TP53 (0.32) | TP53ALDH1A1TSHRMEN1GAA | |
| SCHEMBL3336089 | 0.81 | LMNA (0.30) | — | |
| SCHEMBL27711944 | 0.81 | — | — | |
| SCHEMBL3710459 | 0.81 | PIK3CD (0.30) | — | |
| SCHEMBL6336329 | 0.79 | — | — | |
| SCHEMBL8023425 | 0.79 | TSHR (0.30) | ALDH1A1TSHR | |
| SCHEMBL25381775 | 0.78 | MEN1 (0.31) | ALDH1A1TSHRMEN1GAAKMT2A | |
| SCHEMBL28785662 | 0.78 | — | — | |
| SCHEMBL5511498 | 0.78 | — | — | |
| SCHEMBL8438763 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023167944-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-0625976-A1 | MIXTURES OF OPTICALLY ACTIVE CYCLOHEXENONE OXIME ETHERS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES. | BASF AG (DE) | 1994-11-30 | — | — | EP | disclosed |
| US-5326486-A | Useful with hydrogenated fluorocarbon refrigerants, carbonate compounds and carbonate modified polyethers | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-05 | — | — | US | disclosed |
| WO-1994004489-A1 | CYCLOHEXENONOXIME ETHERS, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-03 | — | — | WO | disclosed |
| WO-1993016063-A1 | CYCLOHEXENONE OXIME ETHERS, PROCESS FOR MAKING THEM AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993016062-A1 | MIXTURES OF OPTICALLY ACTIVE CYCLOHEXENONE OXIME ETHERS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993016061-A1 | MIXTURES OF OPTICALLY ACTIVE CYCLOHEXENONE OXIME ETHERS, PROCESS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993016033-A1 | CYCLOHEXENONE OXIME ETHERS, METHODS OF PREPARING THEM AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993011669-A1 | USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-24 | — | — | WO | disclosed |
| CN-1072948-A | Lubricating oil composition | MITSUI PETROCHEMICAL IND (JP) | 1993-06-09 | — | — | CN | disclosed |
| EP-0534735-A1 | Lubricating oil composition | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | TYMP, PNP, SAMHD1 | TP53 1829/4885ALDH1A1 770/4885TSHR 4630/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TP53 186/4885ALDH1A1 1784/4885TSHR 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.